• Klaus Schaffler, Ashraf Yassen, Peter Reeh, and Paul Passier.
• Human Pharmacodynamic Research (HPR) Dr. Schaffler GmbH, Munich, Germany.
• Pain Med. 2018 Jun 1; 19 (6): 1206-1218.

ObjectivesTo evaluate the analgesic/antihyperalgesic effect of ASP8477.DesignRandomized, double-blind, double-dummy, cross-over, placebo- and active comparator-controlled study.SettingHPR Dr. Schaffler GmbH, Munich, Germany.SubjectsHealthy female subjects aged 18-65 years.MethodsEligible subjects were randomly assigned to one of six treatment sequences and received multiple ascending doses of ASP8477, duloxetine, and placebo over three treatment periods (each consisting of 21-day dosing separated by 14-day washout periods). On the last day of each dose level, laser evoked potentials (LEPs) and visual analog scales (VAS pain) on capsaicin-treated skin at baseline and at multiple postdose time points were assessed. The primary end point was the difference in LEP N2-P2 peak-to-peak (PtP) amplitudes for ASP8477 100 mg vs placebo.ResultsTwenty-five subjects were randomized. In all subjects, LEP N2-P2 PtP amplitudes were numerically lower for ASP8477 100 mg vs placebo (P = 0.0721); in subjects who demonstrated positive capsaicin skin effects, a greater mean difference of -2.24 µV (P = 0.0146) was observed. Across all doses, LEP N2-P2 PtP amplitudes were lower for duloxetine compared with ASP8477 (mean difference -3.80 µV; P < 0.0001) or placebo (mean difference -5.21 µV; P < 0.0001). The effect of ASP8477 (all doses) on down-scoring the VAS pain score was significant compared with placebo (mean difference -2.55%; P < 0.0007).ConclusionsASP8477 was well tolerated in this study. Analysis of all subjects did not demonstrate a significant difference in LEP for ASP8477 100 mg over placebo but did in subjects who demonstrated positive capsaicin skin effects.

18 keywords...

hide…